Badanie nad mekaserminą rinfabate w leczeniu przewlekłej choroby płuc u skrajnie wcześniaków

Chronic Lung Disease is a condition that often affects babies born very early. This study is looking at a new treatment called Mecasermin rinfabate, also known by the code name OHB-607. The purpose of the study is to see if this treatment can help prevent a specific type of lung disease in premature babies, known as Bronchopulmonary Dysplasia (BPD), which is a common cause of chronic lung problems in these infants.

The study will compare the effects of OHB-607 with the usual care given to these babies. The treatment is given as a solution through a vein, which is known as an infusion. The study will observe how well the treatment works and how safe it is for the babies. Researchers will look at whether the treatment reduces the number of severe cases of BPD or if it affects the survival of the babies up to a certain age.

Participants in the study will be monitored closely to see how they respond to the treatment. The study will also track any side effects and overall health outcomes. The goal is to find out if OHB-607 can be a better option for preventing lung disease in very premature babies compared to the standard care they currently receive. The study is expected to continue for several years to gather enough information to make a conclusion.